The latest research published in JAMA Internal Medicine demonstrates that physicians and families often continue the flow of medications well beyond the point at which they might prolong or enhance a patients life The practice needlessly inflates the cost of caring for patients near the end of life by an estimated  on average every  days   An earlier version of this post misspelled the name of Dr Greg A Sachs author of an invited editorial This version corrects that error  Alzheimers disease drugs which are virtually ineffective in patients with severe dementia were the questionable medications most commonly given to nursing home patients with advanced disease Prescriptions for Alzheimers drugs such as donepezil better known by its commercial name Aricept rivastigmine Exelon and memantine Namenda are commonly initiated for patients in the early stages of the disease and may slow the rate at which they become unable to care for themselves Theres little evidence they improve memory or mental performance in people in late stages of the disease however Despite slim evidence for their use those medications often cause side effects such as fainting and arrhythmia which put patients at high risk of hip fractures and urinary retention More than a third of the studys  nursing home residents with severe dementia were taking one or more of these medications The latest study found regional and ethnic differences in the trend of such questionable prescribing It was highest in the southern and central parts of the Western and Eastern United States where as many as  of such patients took at least one drug of questionable value And it was lowest in the midAtlantic states New England and the mountain states of the West Latinos with dementia were much more likely to get medications of questionable value   did so  and the rate for noLatino blacks and whites was roughly the same  about  Men were more likely than women to get such drugs  versus  got medically questionable medications And although medications of questionable value went to  of patients in hospice care and nearly half who had donotresuscitate orders these patients were much less likely than patients outside of the hospice system  and those without donotresuscitate order  to get them In an invited editorial geriatrician and palliative care specialist Dr Greg A Sachs expressed hope that the latest findings will prompt physicians who treat any patients with limited time horizons to reconsider their prescribing practices